kaal:position:2026-07-31-5401

Fidelity of a BAC-EGFP transgene in reporting dynamic expression of IL-7Rα in T cells should be assessed against Kaal's source-bound claim that Exponential disruptive innovation has the potential to overwhelm the existing regulatory process outright, not merely to strain it. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

Apply only within the source-bound Kaal claim's stated scope.
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Fidelity of a BAC-EGFP transgene in reporting dynamic expression of IL-7Rα in T cells

Scholarly basis

kaal:claim:2740477-003
Wulf A. Kaal, Erik P.M. Vermeulen, Venture Capital as Dynamic Regulation of Disruptive Innovation (2016). SSRN: https://ssrn.com/abstract=2740477
Source PDF sha256: c72871b76fa2ad5a8a69ee8d3defc8f64e624be9052ce763e79cf6c58883f726

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2069
Mapping ambiguous: true

Topics

innovationregulatory-failuredynamic-regulation

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0022 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: f5d3b5c6d6d48bc8eefcf966d9a29adc18ca4d7da71f82300e0dea42c2944d07
curl -s https://wulfkaal.github.io/positions/2026-07-31-5401.md | sha256sum